-
Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill
Wednesday, November 17, 2021 - 9:09am | 264Read More...Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month after the drug failed in a small study. Roche and Atea teamed up last year to develop the oral treatment, AT-527, with...
-
Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
Tuesday, August 31, 2021 - 12:10pm | 429Read More...Mesoblast Limited (NASDAQ: MESO) shares dived on Tuesday as the FDA raised more questions around its flagship drug candidate, and its annual loss widened. What Happened: In the June quarter, Mesoblast met FDA on potential regulatory approval of remestemcel-L, used to treat...
-
Novartis Beefs Up Radioligand Portfolio With iTheranostics Deal
Tuesday, March 30, 2021 - 12:51pm | 244Read More...Just a week after acing Phase 3 study evaluating radioligand therapy in prostate cancer, Novartis AG (NYSE: NVS) is licensing the rights to develop and commercialize treatments based on a library of radioligand compounds from iTheranostics, a subsidiary of Sofie...
-
Humanigen Stock Is Trading Higher As Lenzilumab Improves Survival In Hospitalized COVID-19 Patients
Monday, March 29, 2021 - 7:40am | 240Read More...Humanigen Inc (NASDAQ: HGEN) has reported topline data from Phase 3 study evaluating its lead drug candidate, lenzilumab, in patients hospitalized with COVID-19. The 520-patient study demonstrated that lenzilumab significantly improved patient outcomes. Results showed that...
-
GSK Kick Starts Late-Stage Study With Medicago-Partnered COVID-19 Vaccine
Tuesday, March 16, 2021 - 11:08am | 514Read More...GlaxoSmithKline Plc (NYSE: GSK) hopes for better luck with its second partner Medicago, after tripping up in a recent COVID-19 vaccine test with Sanofi SA (NASDAQ: SNY). GSK and Medicago will start Phase 3 testing of Medicago’s COVID-19 vaccine...
-
Regeneron/Sanofi Boast Positive Overall Survival Results In Late-Stage Cervical Cancer Study
Monday, March 15, 2021 - 6:41am | 364Read More...Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed that they’re stopping a Phase 3 cervical cancer trial early after Libtayo showed cutting the risk of death by 31% over chemotherapy. The Independent data monitoring committee...
-
Eli Lilly Reports More Positive Data From Combination Antibody Drug In COVID-19 Trial
Wednesday, March 10, 2021 - 10:28am | 286Read More...Eli Lilly and Co (NYSE: LLY) has announced new data from BLAZE-1 Phase 3 study, evaluating the combination of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg in COVID-19 patients. The combination antibody significantly reduced COVID-19 related...
-
AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study
Monday, February 22, 2021 - 1:29pm | 338Read More...AbbVie Inc (NYSE: ABBV) announces data from the second Phase 3 study, U-ACCOMPLISH, evaluating upadacitinib in patients with moderate to severe ulcerative colitis. The study met the primary and secondary endpoints. 33% of patients receiving upadacitinib achieved clinical remission...
-
Cassava Sciences To Start Two Pivotal Trials With Simufilam In Alzheimer's
Monday, February 22, 2021 - 1:19pm | 339Read More...Cassava Sciences Inc (NASDAQ: SAVA) completes an End-of-Phase 2 (EOP2) meeting with the FDA for its lead candidate, simufilam, in Alzheimer's disease. The FDA and Cassava Sciences agree on key elements of a pivotal Phase 3 program for simufilam, which would include two...
-
Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies
Friday, February 19, 2021 - 2:08pm | 200Read More...Astellas Pharma Plc (OTCMKTS: ALPMY) has reported positive topline results from two Phase 3 trials, SKYLIGHT 1 and SKYLIGHT 2, evaluating an oral non-hormonal compound, fezolinetant, for treating moderate to severe vasomotor symptoms (VMS), specifically hot flashes associated with...
-
Eli Lilly's Tirzepatide Reduces A1C And Body Weight, Late-Stage Studies In Type 2 Diabetes Show
Wednesday, February 17, 2021 - 9:58am | 425Read More...Eli Lilly And Co (NYSE: LLY) have announced topline results from two Phase 3 studies, SURPASS-3 and SURPASS-5, evaluating Tirzepatide in adults with type 2 diabetes. Data showed that Tirzepatide led to significant A1C and body weight reductions from baseline...
-
Travere Therapeutics Shares Rally On Interim Sparsentan Data In Late-Stage Kidney Disorder Study
Tuesday, February 2, 2021 - 10:26am | 392Read More...Travere Therapeutics Inc (NASDAQ: TVTX) share gains after announcing positive interim results from the ongoing Phase 3 DUPLEX study evaluating sparsentan in focal segmental glomerulosclerosis (FSGS), a rare kidney condition that often leads to end-stage kidney disease...
-
Caladrius Biosciences Plunges After Discontinued Phase 3 Study, Announces 'Comprehensive Review' Of Business
Thursday, January 7, 2016 - 9:26am | 167Read More...Caladrius Biosciences Inc (NASDAQ: CLBS), a penny-stock clinical-stage biopharmaceutical company announced after Wednesday's market close it will discontinue an ongoing Phase 3 study. Shares of Caladrius Biosciences plunged nearly 40 percent following the announcement. Caladrius...
